EASD 2021 In patients with diabetes, included in the Hoorn Diabetes Care System cohort, measures of kidney disease, eGFR and UACR, were differentially associated with subtypes of CVD.
ESC 2021 Prof. Casadei gives her opinion about what we should do with the evidence from the Salt Substitute and Stroke Study (SSaSS), which showed that switching to a salt substitute reduces the risk of stroke, CV events and death.
ESC 2021 Prof. Bruce Neal discusses the results of the SSaSS study which showed that replacing dietary salt with a salt substitute reduced stroke, CV events and death, without increasing the risk of hyperkalemia.
ESC 2021 The Salt Substitute and Stroke Study (SSaSS) showed that replacement of salt (100% NaCl) with a salt substitute (75% NaCl + 25% KCl) reduces the risk of stroke in people with prior stroke or hypertension.
ESC 2021 The LOOP study showed that continuous heart rhythm monitoring using an implantable loop recorder and initiation of OAC if AF was detected, did not prevent stroke in patients at high risk compared to standard care.
A randomized clinical trial compared the rate of detection of AF with use of an implantable loop recorder for 12 months vs. use of an external loop recorder for 30 days in patients with recent ischemic stroke without known AF.
The predictive performance of six risk scores for ischemic stroke in patients with AF and CKD were validated. The Modified CHADS2 score showed good performance for discrimination and calibration in all kidney function categories.
ACC 2021 The ADAPTABLE trial demonstrated similar effectiveness with 81 mg vs. 325 mg of daily aspirin in patients with established ASCVD. Also, major bleeding events were comparable between patients taking low-dose or regular-strength aspirin.
This meta-analysis showed that patients without an indication for oral anticoagulation experienced fewer combined thromboembolic and bleeding events, and no increase in thromboembolic events after TAVI when treated with aspirin compared to those receiving DAPT.
This study described the clinical features of 23 patients who after receiving the first dose of ChAdOx1 nCoV-19 vaccine developed atypical platelet factor 4 (PF4)-dependent thrombosis and/or thrombocytopenia that resembles heparin-induced thrombocytopenia.
This study validated six risk scores for ischemic stroke in patients with AF across the spectrum of kidney function. The Modified CHADS2 score showed most consistent predictive performance in all kidney function categories.
Lower dose edoxaban regimen decreased the net clinical outcome of major bleeding, stroke/systemic embolism, and death compared to higher dose edoxaban regimen in patients with AF.